ELEPSIA XR
Clinical safety rating
cautionComprehensive clinical and safety monograph for ELEPSIA XR (ELEPSIA XR).
Levetiracetam, the active component, binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. The exact mechanism of antiepileptic effect is unknown.
| Metabolism | Partially hydrolyzed by esterases in plasma and tissues; minor metabolism via CYP450 enzymes (CYP3A4, CYP2C9, CYP2C19) to inactive metabolites. Approximately 66% excreted unchanged in urine. |
| Excretion | Primarily renal (70% unchanged, 20% as inactive metabolites); minor fecal (10%). |
| Half-life | Terminal elimination half-life is 14-17 hours; requires dose adjustment in renal impairment. |
| Protein binding | 92-97% bound to serum albumin. |
| Volume of Distribution | 0.9-1.1 L/kg; indicates moderate extravascular distribution. |
| Bioavailability | Oral: Approximately 80% with food; may be lower on empty stomach. |
| Onset of Action | Oral: 30-60 minutes for therapeutic effect. |
| Duration of Action | Dosing interval of 12 hours due to biphasic release; clinical effect persists for the full interval. |
| Molecular Weight | 326.39 |
ELEPSIA XR (levetiracetam extended-release) 1000 mg orally once daily. May be increased by 1000 mg/day every 2 weeks to a maximum of 3000 mg once daily.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For creatinine clearance (CrCl) 50-80 mL/min: 1000 mg every 24 hours. CrCl 30-49 mL/min: 500 mg every 24 hours. CrCl <30 mL/min: 250 mg every 24 hours. End-stage renal disease on dialysis: 500 mg every 24 hours with a supplemental dose of 500 mg after dialysis. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment required. Severe hepatic impairment (Child-Pugh C): Reduce dose by 50%; for CrCl <60 mL/min, adjust both for renal function and hepatic impairment. |
| Pediatric use | ELEPSIA XR is not indicated for pediatric patients. Immediate-release levetiracetam dosing for pediatric epilepsy: 20 mg/kg/day in two divided doses, titrated up to 40-60 mg/kg/day based on response; maximum 3000 mg/day for children ≥12 years. |
| Geriatric use | Elderly patients (>65 years) often have reduced creatinine clearance. Adjust dose based on renal function (see renal_adjustment). Start at lower end of dosing range; monitor for somnolence and dizziness. |
| 1st trimester | Teratogenic risk cannot be ruled out; avoid use unless benefits outweigh risks. |
| 2nd trimester | May cause fetal harm; consider alternative therapies. |
| 3rd trimester | Risk of neonatal withdrawal and respiratory depression; avoid use near term. |
Clinical note
Comprehensive clinical and safety monograph for ELEPSIA XR (ELEPSIA XR).
| Placental transfer | Crosses placenta; detected in cord blood at 50-80% of maternal plasma concentration. |
| Breastfeeding | Excreted in breast milk; monitor infant for sedation and poor feeding. Use only if clearly needed. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and cardiac defects due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction, preterm birth, and neonatal hemorrhage. Third trimester: Potential for kernicterus and transient neonatal hemolytic anemia. Antiepileptic Drug (AED) use in pregnancy overall associated with developmental delay and autism spectrum disorder. |
| Fetal Monitoring | Maternal: Serum AED levels every 4 weeks during pregnancy, liver function, CBC, and coagulation profile. Fetal: High-resolution ultrasound at 18-20 weeks for structural anomalies. Neonatal: CBC, bilirubin, coagulation screen, and observation for withdrawal symptoms (irritability, hypertonia) after delivery. |
| Fertility Effects | May reduce efficacy of oral contraceptives; consider non-hormonal contraception. No direct alteration of fertility, but teratogenic risks warrant careful family planning. |
■ FDA Black Box Warning
Not applicable (no FDA boxed warning).
| Serious Effects |
Hypersensitivity to active substance or excipientsConcurrent use with MAOIsSevere hepatic impairment (Child-Pugh C)
| Precautions | Psychiatric adverse reactions: including agitation, hostility, aggression, anxiety, and paranoid reactions, which may be severe. Monitor for behavioral changes., Suicidal ideation and behavior: increased risk of suicidal thoughts or behavior in patients taking antiepileptic drugs. Monitor for emergence or worsening of depression., Somnolence and dizziness: common, impairing ability to drive or operate machinery., Withdrawal seizures: abrupt discontinuation may increase seizure frequency. Taper gradually. |
| Food/Dietary | Avoid high-fat meals as they may delay absorption. No specific food restrictions, but maintain adequate hydration to prevent nephrolithiasis. |
| Clinical Pearls | ELEPSIA XR (topiramate extended-release) is indicated for epilepsy and migraine prophylaxis. Titrate slowly to minimize cognitive side effects. Monitor for metabolic acidosis, especially in patients with predisposing conditions. Contraindicated in pregnancy due to risk of oral clefts. Adjust dose in renal impairment (CrCl <70 mL/min). |
| Patient Advice | Swallow capsules whole; do not crush or chew. · Take with or without food; avoid high-fat meals which may delay absorption. · May cause dizziness, drowsiness, or blurred vision; avoid driving until effects known. · Drink plenty of fluids to reduce risk of kidney stones. · Stop taking and contact doctor if you experience eye pain, vision changes, or fever. · Use effective contraception during treatment; inform doctor if pregnant or planning pregnancy. |
Loading safety data…